Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Won't be 'same ole, same ole' for ODAC at Perjeta meeting

This article was originally published in Scrip

Executive Summary

When the FDA's Oncologic Drugs Advisory Committee (ODAC) meets on 12 September to review the supplemental biologics license application (sBLA) for Genentech's Perjeta (pertuzumab), a humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER2 tyrosine kinase receptor, the panel will have some new topics of discussion on the table.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register